FY2025 was either a regime change or the third margin breakout in five years that reverts.

• The breakout. FY2025 printed four straight quarters of positive operating income for the first time in the dataset, EBITDA of C$3.18M (+37% YoY) and free cash flow of C$4.63M (5.5x FY2024) on revenue growth of just 8.8%. Operating margin reached 12.5% — the highest since 2021.
• The pattern. Operating margin has flipped sign eight times in twenty years. FY2020 hit 19.5% then collapsed to 2.3% by FY2022; FY2021 hit 18.6% then collapsed to -1.0% by FY2023. The Quant Predictability score is 1 of 5 for exactly this reason.
• The resolving signal. Q1 FY2026 reports May 15 and is binary. Above 10% operating margin tips the read to structural. Below 8% snaps the multiple back to the FY2022-FY2024 sawtooth and the stock to ~C$0.22.

Cash generation stepped up 5.5x in a single year on flat revenue growth — that is the FY25 story in one fact.

Cost of revenue is just 17% of sales, so once revenue clears the fixed-cost line every incremental claim drops through. FY2025 was the first year that fixed costs stopped catching up. The trailing five-year FCF/NI ratio is 1.7x — depreciation on the platform stack absorbs accounting earnings while cash keeps moving. For the multiple to hold, FY2026 has to repeat at C$3-5M FCF. Anything closer to FY2022-2024's C$0.6-1.0M range and 6.5x P/FCF instantly looks expensive.

A successful small business that finally learned to print cash, masquerading as a public stock.

Build (2003-2014): Founder Ron Loucks (ex-COO of Assure Health, sold to BCE Emergis in 1999) built NexgenRx as the only independent TPA in a market owned by Sun Life, Manulife, and Canada Life. Ten consecutive years of net losses, an IPO at C$5.2M in 2006, and an all-time low of C$0.085 in August 2014.

Pivot: Two acquisitions in August 2018 — Canadian Benefit Administrators and My Benetech — pushed revenue from C$7.2M to C$9.5M. FY2020 delivered the first non-token profit (C$2.1M NI). FY2022 declared the first dividend. The narrative quietly stopped saying 'transformation' and started saying 'continuation.'

Today: A C$28M market cap, C$17.9M revenue, 17.8% EBITDA margin business with zero debt, C$4.8M cash, and a payout ratio sitting at exactly 1.0x. The next chapter answers a single question: does FY25 cash flow durability prove out, or does the sawtooth resume?

Founder-aligned, founder-dependent — and a 20% holder nobody can explain.

• Loucks (CEO, 23 years). Owns 10.5% of common plus 13.8% of the unlisted Series 1 preferred — roughly C$2.4M of stock against C$313K cash comp. Bought 120,000 shares in May 2024 at C$0.28. No named successor, no President, no COO after 23 years.
• Paul Crossett (20.07%). Largest common holder, classified as insider, no board seat, no public bio, no proxy history. A passive anchor or a control block outside the governance wall — the data cannot tell you which.
• The Burns reversal. At the May 2024 AGM, director Charles Burns lost his majority vote and resigned per policy. The board re-appointed him 21 weeks later, on Oct 7, 2024. The letter of the policy was followed; the spirit was not. Insiders aggregate to ~37% of common — a hostile bid cannot win without Loucks and Crossett.

Three earnings prints, one AGM, two dividend declarations — the entire next six months.

• May 15 — Q1 FY2026 results. The single binary print. Operating margin above 10% on revenue at or above C$4.5M validates the FY25 inflection. Below 8% confirms reversion and likely retests the C$0.27 low.
• Mid-June — Annual General Meeting. The realistic window for a named successor, President, or COO. Silence here keeps the key-man discount intact; an explicit succession announcement is the one disclosure that re-rates the governance grade.
• Aug 15 and Nov 20 — Q2 and Q3 prints. Sequential confirmation. Two consecutive 12%+ operating-margin quarters plus a named successor would be the cover signal even bears acknowledge. There is no analyst coverage, no consensus, no guidance — every print is the catalyst.